A. Redondo

Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.
20247 citationsauthor #3
Updated Review and Clinical Recommendations for the Diagnosis and Treatment of Patients with Retroperitoneal Sarcoma by the Spanish Sarcoma Research Group (GEIS)
202311 citationsauthor #19
The combination of APR-246 and carboplatin in olaparib-resistant high grade serous ovarian cancer (HGSOC) and triple negative breast cancer (TNBC) cell lines.
20230 citationsauthor #6
Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry
202317 citationsauthor #22
Spatial distribution of CD3- and CD8-positive lymphocytes as pretest for POLE wild-type in molecular subgroups of endometrial carcinoma
20231 citationsauthor #14
Comparison of Methods for Testing Mismatch Repair Status in Endometrial Cancer
202314 citationsauthor #12
Evaluation of Immune Infiltrates in Ovarian Endometriosis and Endometriosis-Associated Ovarian Cancer: Relationship with Histological and Clinical Features
20232 citationsauthor #14
Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03
20236 citationsauthor #5
Efficacy of second and third lines of treatment in advanced soft tissue sarcomas: a real-world study
20234 citationsauthor #17
Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS)
202338 citationsauthor #4
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.
202390 citationsauthor #10
The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma—A Study by the Spanish Group for Ovarian Cancer Research (GEICO)
20234 citationsauthor #4
Abstracts of the 12th International Charité Mayo Conference on “Global Perspectives and Future Directions in Women’s Cancer”
20230 citationsauthor #6
European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 2023
2023171 citationsauthor #11
AXL pathway as a target to overcome resistance to PARP inhibitors in high-grade serous ovarian (HGSOC) and triple-negative breast cancer (TNBC) cell lines.
20231 citationsauthor #7
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer.
20237 citationsauthor #19
SELISARC: A Spanish Sarcoma Group (GEIS) phase I/II trial of selinexor plus gemcitabine in selected sarcoma subtypes—Results of the phase I part.
20230 citationsauthor #5
Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601
20234 citationsauthor #10
Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus
20233 citationsauthor #1
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
20227 citationsauthor #13
Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study
20229 citationsauthor #4
Prognostic value of EZH2 expression for immunotherapy-based schemes in advanced soft-tissue sarcoma: A translational research from Spanish Group of Research on Sarcoma (GEIS).
20220 citationsauthor #8
2022-RA-1074-ESGO AGO-OVAR 2.29 (ENGOT-ov34): atezolizumab in combination with bevacizumab and chemotherapy vs bevacizumab and chemotherapy in recurrent ovarian cancer
20220 citationsauthor #6
O025/#522 Maintenance olaparib rechallenge in patients with ovarian cancer previously treated with a parp inhibitor: patient-reported outcomes from the phase IIIB OReO/engot-ov38 trial
20220 citationsauthor #1
A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors
20224 citationsauthor #2
Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib
20221 citationsauthor #6
Dostarlimab for the treatment of advanced endometrial cancer
202220 citationsauthor #1
Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab
202212 citationsauthor #3
Prognostic markers of inflammation in endometrioid and clear cell ovarian cancer
202214 citationsauthor #12
Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects
20227 citationsauthor #4
Antitumoral Effect of Plocabulin in High Grade Serous Ovarian Carcinoma Cell Line Models
20222 citationsauthor #13
LIO-1: Initial phase 2 experience of lucitanib + nivolumab in patients with metastatic or recurrent cervical cancer (NCT04042116; ENGOT-GYN3/AGO/LIO) (034)
20223 citationsauthor #10
Inflammatory indexes neutrophils/lymphocytes, platelets/lymphocytes and red-cell distribution width (RDW) as prognostic biomarkers in advanced solitary fibrous tumors (SFT) treated with pazopanib: Correlative study of GEIS-32 trial.
20210 citationsauthor #6
LBA33 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial
202150 citationsauthor #20
Prognostic implications of tumor-infiltrating T cells in early-stage endometrial cancer
202125 citationsauthor #15
734P Neutrophil-lymphocyte ratio predicts survival in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD): Stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601
20210 citationsauthor #10
Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?
20216 citationsauthor #7
Real-world clinical practice patterns and outcomes for advanced ovarian cancer in Spain (GEICO-42-R study)
20211 citationsauthor #1
Quality-adjusted time without symptom or toxicity and quality-adjusted progression-free survival of first-line maintenance niraparib in patients with advanced ovarian cancer
20210 citationsauthor #13
A phase Ib/II study of selinexor in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST): SeliGIST/GEIS-41 trial.
20211 citationsauthor #7
Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combination with other drugs improve its antitumoral effect?
20219 citationsauthor #14
Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS -GROUP). Part II.
202112 citationsauthor #12
Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS - GROUP). Part I.
202113 citationsauthor #14
Management of advanced ovarian cancer in Spain: an expert Delphi consensus
20214 citationsauthor #1
Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer
202144 citationsauthor #5
Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma
202140 citationsauthor #10
Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)
202124 citationsauthor #11
Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: A combined analysis of two cohorts in the GARNET study.
202130 citationsauthor #8
GEIS 39: Phase II trial of nabpaclitaxel for the treatment of patient with multiply relapsed/refractory desmoplastic small round cell tumor (DSRCT) and Ewing sarcoma (EwS).
20211 citationsauthor #5
Prognosis Stratification Tools in Early-Stage Endometrial Cancer: Could We Improve Their Accuracy?
20216 citationsauthor #20
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
2021252 citationsauthor #11
Health-related quality of life (QoL) in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD), a multicenter single-arm phase II clinical trial (ROLANDO, GEICO-1601).
20211 citationsauthor #10
1536P Biological processes associated with the efficacy of sunitinib plus nivolumab in soft-tissue sarcoma: Correlative studies of the IMMUNOSARC trial of Spanish (GEIS) and Italian (ISG) sarcoma groups
20210 citationsauthor #9
798P A phase II study of pembrolizumab (P) in combination with doxorubicin (D) in advanced endometrial cancer (AEC): TOPIC trial/VHIO10001
20212 citationsauthor #3
Long-term response to olaparib in BRCA1-related ovarian cancer with brain metastases
20218 citationsauthor #6
Proteomic Analysis of Low-Grade, Early-Stage Endometrial Carcinoma Reveals New Dysregulated Pathways Associated with Cell Death and Cell Signaling
202138 citationsauthor #16
731 Biomarker analysis of the phase 2 study of pembrolizumab in combination with doxorubicin in advanced endometrial cancer: TOPIC trial/VHIO10001
20212 citationsauthor #5
Tumor infiltrating lymphocytes (TILs) in endometrioid and clear cell ovarian carcinoma: Characterization, association with mismatch repair system deficiency and endometriosis, and prognostic implications.
20212 citationsauthor #10
738P Quality-adjusted time without symptom or toxicity (QA-TWiST) and quality-adjusted progression-free survival (QA-PFS) of first-line (1L) maintenance niraparib in patients with advanced ovarian cancer (OC): Results from the PRIMA trial
20215 citationsauthor #13
Retrospective world-wide registry on the efficacy of immune checkpoint inhibitors in alveolar soft part sarcoma: Updated results from sixty patients.
20213 citationsauthor #16
LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study
202018 citationsauthor #11
32P Comparison of fully automated microsatellite instability test to immunohistochemistry for mismatch repair protein expression in endometrial carcinoma
20200 citationsauthor #16
Cancer survivors referred to a long-term survivorship outpatient service within academic medical oncology: descriptive study
20206 citationsauthor #9
Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer
202021 citationsauthor #12
862P Prognostic role of CD3, CD4, CD8 and FOXP3 positive populations in early-stage endometrial carcinoma
20200 citationsauthor #14
Patient-reported outcomes (PRO) in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab in the GARNET trial.
20202 citationsauthor #3
Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial
2020147 citationsauthor #5
The hallmarks of ovarian cancer: Focus on angiogenesis and micro-environment and new models for their characterisation
202013 citationsauthor #3
Prognostic value of neutrophil-to-lymphocyte ratio and other inflammatory markers in patients with high-risk soft tissue sarcomas
202025 citationsauthor #18
ENGOT-OV44/FIRST study: a randomized, double-blind, adaptive, phase III study of standard of care (SOC) platinum-based therapy ± dostarlimab followed by niraparib ± dostarlimab maintenance as first-line (1L) treatment of stage 3 or 4 ovarian cancer (OC).
202011 citationsauthor #5
Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.
202040 citationsauthor #1
Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial.
202069 citationsauthor #16
Are antiangiogenics a good ‘partner’ for immunotherapy in ovarian cancer?
202017 citationsauthor #2
Trabectedin and radiotherapy in soft-tissue sarcoma (TRASTS) study: An international, prospective, phase II trial in localized myxoid liposarcoma—A collaborative Spanish (GEIS), Italian (ISG) and French (FSG) group study.
20208 citationsauthor #4
Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?
202011 citationsauthor #12
832P GEICO1601-ROLANDO trial: A multicentric single arm phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer
20200 citationsauthor #10
858P Patient-reported outcomes (PROs) in the GARNET trial in patients (pts) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (dMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab
20201 citationsauthor #3
IMMUNOSARC: a collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib and nivolumab in advanced soft tissue and bone sarcoma: Results from the phase II part, bone sarcoma cohort.
202019 citationsauthor #4
CANCER CELL STEMNESS AND COLLAGEN REGULATORS OF STEMNESS IN UTERINE SEROUS CARCINOMA (USC) MIRROR OVARIAN SEROUS CANCER (OSC) CELL STEMNESS: EVIDENCE EMERGING FROM ARK1-USC
20200 citationsauthor #3
Patient-reported outcomes (PRO) in the GARNET trial in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab.
20202 citationsauthor #3
Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: a single-institution experience
202028 citationsauthor #11
Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial.
202039 citationsauthor #21
860P Redefining prognosis in early-stage high-grade endometrial cancer
20200 citationsauthor #16
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)
202013 citationsauthor #5
1624MO Weekly nab-paclitaxel for progressive or symptomatic desmoid tumors: A multicenter single arm phase II trial from the Spanish Group for Research on Sarcoma (GEIS)
20201 citationsauthor #3
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
20191,641 citationsauthor #13
Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer
20191,963 citationsauthor #10
3D culture modelling: An emerging approach for Translational Cancer Research in Sarcomas.
20195 citationsauthor #2
AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC).
20195 citationsauthor #5
Bevacizumab combined with first-line carboplatin and paclitaxel for metastatic/recurrent/persistent cervical cancer: primary results from the global single-arm phase II CECILIA study
20190 citationsauthor #10
Incidence of vascular thromboembolism events in cancer patients receiving immunotherapy: A single institution experience
20196 citationsauthor #11
Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.
201971 citationsauthor #3
Abstract GS1-10: Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE
201916 citationsauthor #10
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer
201914 citationsauthor #18
ENGOT-OV44/FIRST study: A randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR-042) + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3/4 non-mucinous epithelial ovarian cancer (OC).
201920 citationsauthor #5
Myoinvasive Pattern as a Prognostic Marker in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma
201926 citationsauthor #10
Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab (BEV), carboplatin (C) and paclitaxel (P) for advanced cervical cancer (aCC)
20194 citationsauthor #1
Trabectedin with concurrent low-dose of radiation therapy for metastatic soft tissue sarcomas: A phase II trial of Spanish, French and Italian sarcoma groups
20190 citationsauthor #10
Influence of eribulin on proliferation, migration and invasion properties of leiomyosarcoma cell line models
20190 citationsauthor #12
Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
2019111 citationsauthor #4

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT